Multivalent pneumococcal vaccine
We are developing a high-valent pneumococcal conjugate vaccine using Inventprise’s proprietary conjugation technology for pediatric populations globally. In addition, Inventprise is working on an adult formulation intended for use world wide.
The value of the pneumococcal vaccines market will steadily grow over from USD 7.2 billion (2019) to over USD 11 billion by 2030 representing the second largest segment of the vaccine industry (measured by dollar volume)..
IVT-PCV-25 leverages our proprietary technology platform to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by children. Each one of these serotypes has been carefully evaluated and determined to be critical for the protection of children under the age of 5 regardless of which country they live.
Currently in late stage preclinical development, IVT-PCV-25 will be indicated for immunization for the prevention of invasive pneumococcal disease and otitis media. Proof of concept clinical trials are expected to begin in 2022.